Health Care & Life Sciences » Pharmaceuticals | Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc. Cl A
Stock Exchange Frankfurt Stock Exchange
EPS
EUR1.67
Market Cap
EUR1.46 B
Shares Outstanding
139.18 M
Public Float
81.38 M
Ironwood Pharmaceuticals Inc. Cl A
Stock Exchange NASDAQ Stock Market
EPS
$1.94
Market Cap
$1.63 B
Shares Outstanding
155.62 M
Public Float
150.02 M

Profile

Address
301 Binney Street
Cambridge Massachusetts 02142
United States
Employees -
Website http://www.ironwoodpharma.com
Updated 07/08/2019
Ironwood Pharmaceuticals, Inc. operates as commercial biotechnology company, which discovers, develops and commercializes differentiated medicines that improve patient's lives. Its products include linaclotide, a guanylate cyclase type-C agonist being developed for the treatment of patients with irritable bowel syndrome with constipation and chronic constipation; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout. The company was founded by Peter M.

Financials

View All
Created with Highcharts 5.0.14Ironwood Pharmaceuticals Inc. Cl ANet Income. Fiscal year is January-December. All values USD Thousands.272 812272 812189 618189 618142 669142 66981 70881 708116 937116 937282 368282 368201320142015201620172018050k100k150k200k250k300k
Created with Highcharts 5.0.14Ironwood Pharmaceuticals Inc. Cl ASales/Revenue. Fiscal year is January-December. All values USD Thousands.22 88122 88176 43676 436149 555149 555273 957273 957298 276298 276346 639346 6392013201420152016201720180100k200k300k400k

Peter M. Hecht
Chief Executive Officer & Director
Terrance G. McGuire
Chairman